Call for Papers
Molecular Autism is currently accepting submissions for a new thematic series, Stem Cells and Autism Research. Manuscripts should be submitted by 31st October 2019. Read more here.
Editors-in-Chief
Simon Baron-Cohen, University of Cambridge, UK
Joseph Buxbaum, Icahn School of Medicine at Mount Sinai, New York
Aims and scope
Molecular Autism is a peer-reviewed, open access journal that publishes high-quality basic, translational and clinical research that has relevance to the etiology, pathobiology, or treatment of autism and related neurodevelopmental conditions. Research that includes integration across levels is encouraged. Molecular Autism publishes empirical studies, reviews, and brief communications.
We encourage submissions from a range of fields including (but not restricted to) genetics, molecular neurobiology, neuropathology, neuroimaging, cognitive neuroscience, epidemiology, and biomarker discovery. Molecular Autism also publishes articles on screening, diagnosis and classification, including articles that consider subgrouping to refine our understanding of basic mechanisms. Intervention studies are also welcome, especially when considered with respect to revealing causal mechanisms.
Joseph Buxbaum, co-Editor-in-Chief
Joseph Buxbaum is a molecular geneticist and neuroscientist, Director of the Seaver Autism Center for Research and Treatment, and Professor at the Icahn School of Medicine at Mount Sinai. Dr Buxbaum is the founder and co-lead investigator of the Autism Sequencing Consortium, an international collaboration to discover genes for autism. He has also been elected to the prestigious National Academy of Medicine (NAM), in recognition of his important contributions to uncovering the genetic and molecular basis of autism.
Simon Baron-Cohen, co-Editor-in-Chief
Simon Baron-Cohen is Professor of Developmental Psychopathology at the University of Cambridge and Fellow at Trinity College, Cambridge. He is also Director of the Autism Research Centre (ARC) in Cambridge and Director of CLASS (Cambridge Lifespan Asperger Syndrome Service), a clinic for adults with suspected AS.
Advertisement
Follow
Annual Journal Metrics
-
Speed
75 days to first decision for reviewed manuscripts only
55 days to first decision for all manuscripts
187 days from submission to acceptance
21 days from acceptance to publicationCitation Impact
5.872 - 2-year Impact Factor
6.188 - 5-year Impact Factor
1.326 - Source Normalized Impact per Paper (SNIP)
2.377 - SCImago Journal Rank (SJR)Usage
462,397 downloads
3412 Altmetric mentions
Advertisement
